Kneat Achieves Record Revenue for Fourth Quarter and Full Year 2025

Why It Matters

The results demonstrate Kneat’s scaling momentum in the high‑growth life‑sciences validation market and signal a path toward cash‑flow breakeven, strengthening its appeal to investors and enterprise customers.

Key Takeaways

• Q4 revenue rose 24% to $17 million.
• SaaS revenue grew 29% to $16.2 million.
• ARR reached $74.1 million, up 24% YoY.
• Adjusted EBITDA hit $9.5 million for full year.
• G2 named Kneat #1 pharma software, 98/100 score.

Pulse Analysis

Kneat’s 2025 performance underscores the accelerating demand for digital validation tools in regulated industries. Life‑sciences companies are under pressure to shorten product cycles while maintaining strict compliance, driving adoption of cloud‑based SaaS platforms like Kneat Gx. By expanding its AI‑powered data‑integrity features and securing a #1 ranking on G2, Kneat differentiates itself from legacy validation solutions, positioning the firm as a trusted partner for large pharmaceutical and biotech enterprises.

Financially, the company posted a 29% revenue jump to $63.3 million and a 33% surge in SaaS sales, reflecting strong cross‑sell and upsell opportunities. Gross margins improved to 76%, and the net loss narrowed dramatically, while adjusted EBITDA climbed to $9.5 million, indicating operational efficiency gains. An ARR of $74.1 million and a net‑revenue‑retention rate of 115% highlight a durable subscription base that can sustain future growth and support the stated goal of cash‑flow breakeven in 2026.

Strategically, Kneat leveraged a landmark partnership with Capgemini to accelerate digital validation across global manufacturing networks, and it introduced new API and AI capabilities that enhance user productivity and regulatory governance. Record wins with multinational enterprises and leadership additions signal a robust pipeline for 2026. Combined with industry accolades and a clear roadmap, these factors suggest Kneat is well‑positioned to capture additional market share as life‑sciences firms continue their digital transformation journeys.